JP6578271B2 - 免疫抑制ＴＧＦ−βシグナルコンバーター - Google Patents

免疫抑制ＴＧＦ−βシグナルコンバーター Download PDF

Info

Publication number
JP6578271B2
JP6578271B2 JP2016509111A JP2016509111A JP6578271B2 JP 6578271 B2 JP6578271 B2 JP 6578271B2 JP 2016509111 A JP2016509111 A JP 2016509111A JP 2016509111 A JP2016509111 A JP 2016509111A JP 6578271 B2 JP6578271 B2 JP 6578271B2
Authority
JP
Japan
Prior art keywords
cell
cells
receptor
cancer
tgfβ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016509111A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520302A (ja
JP2016520302A5 (https=
Inventor
フェルナンド、ヴェラ ヴァルデス、ジュアン
フェルナンド、ヴェラ ヴァルデス、ジュアン
ルーニー、クリオナ、エム．
リーン、アン、マリー
紀宏 渡部
紀宏 渡部
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of JP2016520302A publication Critical patent/JP2016520302A/ja
Publication of JP2016520302A5 publication Critical patent/JP2016520302A5/ja
Application granted granted Critical
Publication of JP6578271B2 publication Critical patent/JP6578271B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2016509111A 2013-04-17 2014-04-17 免疫抑制ＴＧＦ−βシグナルコンバーター Active JP6578271B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361812917P 2013-04-17 2013-04-17
US61/812,917 2013-04-17
PCT/US2014/034570 WO2014172584A1 (en) 2013-04-17 2014-04-17 IMMUNOSUPPRESSIVE TGF-β SIGNAL CONVERTER

Publications (3)

Publication Number Publication Date
JP2016520302A JP2016520302A (ja) 2016-07-14
JP2016520302A5 JP2016520302A5 (https=) 2017-05-25
JP6578271B2 true JP6578271B2 (ja) 2019-09-18

Family

ID=50877664

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016509111A Active JP6578271B2 (ja) 2013-04-17 2014-04-17 免疫抑制ＴＧＦ−βシグナルコンバーター

Country Status (6)

Country Link
US (2) US10584158B2 (https=)
EP (2) EP2986636B1 (https=)
JP (1) JP6578271B2 (https=)
CN (1) CN105452287A (https=)
CA (1) CA2909701C (https=)
WO (1) WO2014172584A1 (https=)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2948544A4 (en) 2013-01-28 2016-08-03 St Jude Childrens Res Hospital CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
CA2909701C (en) * 2013-04-17 2022-12-06 Baylor College Of Medicine Immunosuppressive tgf-.beta. signal converter
CA2921805C (en) 2013-08-22 2023-03-07 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
TWI750110B (zh) 2014-07-21 2021-12-21 瑞士商諾華公司 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
KR20170037625A (ko) 2014-07-21 2017-04-04 노파르티스 아게 Cll-1 키메라 항원 수용체를 사용한 암의 치료
MA41538A (fr) * 2014-10-17 2017-12-26 Baylor College Medicine Cellules immunitaires bipartites et tripartites de signalisation
GB201421716D0 (en) 2014-12-05 2015-01-21 King S College London Cell expansion procedure
EP4400516A1 (en) 2014-12-15 2024-07-17 The Regents of the University of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
EP3234120B1 (en) 2014-12-15 2025-09-03 The Regents of the University of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
US10828353B2 (en) * 2015-01-31 2020-11-10 The Trustees Of The University Of Pennsylvania Compositions and methods for T cell delivery of therapeutic molecules
US20160228547A1 (en) * 2015-02-06 2016-08-11 Batu Biologics, Inc. Chimeric antigen receptor targeting of tumor endothelium
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
WO2016170541A1 (en) 2015-04-21 2016-10-27 Enlivex Therapeutics Ltd. Therapeutic pooled blood apoptotic cell preparations and uses thereof
CA2978186A1 (en) 2015-03-05 2016-09-09 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
EP3283520B1 (en) * 2015-04-13 2020-05-06 Pfizer Inc Chimeric antigen receptors targeting b-cell maturation antigen
GB201513540D0 (en) 2015-07-31 2015-09-16 King S College London Therapeutic agents
HK1256638A1 (zh) 2015-08-04 2019-09-27 Acceleron Pharma Inc. 用於治疗骨髓增生性病症的方法
EP3202792B1 (en) 2015-08-07 2024-08-14 Shenzhen In Vivo Biomedicine Technology Limited Company Chimeric antigen receptor containing intracellular domain of toll-like receptor
DK3368571T5 (da) 2015-10-30 2024-09-30 Univ California Transformerende, vækstfaktor-beta-responsive polypeptider og fremgangsmåder til anvendelse deraf
WO2017100428A1 (en) 2015-12-09 2017-06-15 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of using same
CN109069539A (zh) 2016-02-18 2018-12-21 恩立夫克治疗有限责任公司 用于癌症治疗的联合免疫疗法和细胞因子控制疗法
MX2018010924A (es) * 2016-03-11 2019-02-13 Bluebird Bio Inc Células efectoras inmunitarias con edición genómica.
CN108883181A (zh) * 2016-04-05 2018-11-23 葛兰素史密斯克莱知识产权发展有限公司 在免疫疗法中抑制TGFβ
US11377637B2 (en) 2016-04-15 2022-07-05 Memorial Sloan Kettering Cancer Center Transgenic T cell and chimeric antigen receptor T cell compositions and related methods
CN109312304A (zh) * 2016-04-20 2019-02-05 弗雷德哈钦森癌症研究中心 免疫调节性il2r融合蛋白及其用途
SG11201901642XA (en) * 2016-08-26 2019-03-28 Baylor College Medicine Constitutively active cytokine receptors for cell therapy
CA3034691A1 (en) * 2016-08-30 2018-03-08 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use for treating viral and other infections
US11530395B2 (en) 2016-10-17 2022-12-20 2Seventy Bio, Inc. TGFBetaR2 endonuclease variants, compositions, and methods of use
IL266628B2 (en) * 2016-11-17 2024-06-01 Bluebird Bio Inc TGFBeta signal converter
AU2018236461B2 (en) 2017-03-17 2025-03-27 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
KR102660336B1 (ko) 2017-03-27 2024-04-26 내셔널 유니버시티 오브 싱가포르 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도
LT3628049T (lt) 2017-05-04 2023-08-25 Acceleron Pharma Inc. Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai
CN108853144A (zh) * 2017-05-16 2018-11-23 科济生物医药（上海）有限公司 Toll样受体激动剂与免疫效应细胞的联用
CN110709424B (zh) * 2017-05-31 2024-01-05 科济生物医药（上海）有限公司 细胞免疫治疗的组合物和方法
CN107236762A (zh) * 2017-06-19 2017-10-10 河北浓孚雨生物科技有限公司 一种微环dna转染t细胞制备临床级car‑t细胞制剂的方法
WO2019109980A1 (zh) * 2017-12-06 2019-06-13 科济生物医药（上海）有限公司 嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用
AU2019219454A1 (en) 2018-02-09 2020-08-27 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
MX2020009272A (es) * 2018-03-06 2021-01-08 Univ Pennsylvania Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos.
TWI823906B (zh) 2018-03-09 2023-12-01 美商艾吉納斯公司 抗-cd73 抗體及其使用方法
CN112055717B (zh) 2018-04-02 2024-04-26 新加坡国立大学 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CA3100724A1 (en) 2018-06-13 2019-12-19 Novartis Ag B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
CN112867503A (zh) * 2018-08-24 2021-05-28 希望之城 掩蔽的细胞因子缀合物
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
US12590148B2 (en) 2018-11-26 2026-03-31 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
CN113840920A (zh) * 2019-03-14 2021-12-24 加利福尼亚大学董事会 合并的敲入筛选和在内源基因座控制下共表达的异源多肽
KR20220030933A (ko) 2019-05-08 2022-03-11 메디진 이뮤노테라피스 게엠바하 조작된 t 세포
KR102821463B1 (ko) * 2019-08-15 2025-06-16 난트바이오 인코포레이티드 Tgf-베타 트랩
WO2021041806A1 (en) * 2019-08-30 2021-03-04 Allogene Therapeutics, Inc. Chimeric cytokine receptors comprising tgf beta binding domains
US20230030680A1 (en) * 2020-01-07 2023-02-02 St. Jude Children's Research Hospital, Inc Chimeric gmcsf-il18 receptor
CN113150167A (zh) * 2020-01-22 2021-07-23 中国人民解放军总医院第五医学中心 一种能够反转pd-1免疫抑制信号的car t细胞结构em1设计
CN115698038A (zh) * 2020-06-01 2023-02-03 上海君赛生物科技有限公司 信号转换受体及其用途
AU2021308078A1 (en) * 2020-07-17 2023-02-09 Children's Hospital Los Angeles Chimeric MyD88 receptors for redirecting immunosuppressive signaling and related compositions and methods
CN112210543B (zh) * 2020-07-30 2023-01-03 山东省成体细胞产业技术研究院有限公司 一种针对实体瘤克服TGF-β免疫抑制的CAR-T细胞
WO2022087453A1 (en) * 2020-10-22 2022-04-28 Lyell Immunopharma, Inc. Chimeric activation receptors
EP4247850A1 (en) 2020-11-20 2023-09-27 Simcere Innovation, Inc. Armed dual car-t compositions and methods for cancer immunotherapy
CN116802300A (zh) * 2021-01-15 2023-09-22 国立大学法人东海国立大学机构 嵌合靶因子受体
CN114540311A (zh) * 2022-02-24 2022-05-27 深圳市先康达生命科学有限公司 一种免疫细胞及其应用
CN114525260A (zh) * 2022-02-24 2022-05-24 深圳市先康达生命科学有限公司 一种同时表达融合蛋白及嵌合抗原受体的免疫细胞及其应用
CN119546328A (zh) 2022-04-08 2025-02-28 再生元制药公司 多部分受体和信号传导复合物
EP4403580A1 (en) 2023-01-23 2024-07-24 Medizinische Hochschule Hannover Anti-entpd3 chimeric antigen receptor
KR20250169635A (ko) 2023-01-23 2025-12-03 메디치니쉐 호흐슐레 하노버 항-entpd3 키메라 항원 수용체
IL322333A (en) 2023-02-07 2025-09-01 Quell Therapeutics Ltd Culture method for TREG cells
EP4420676A1 (en) 2023-02-24 2024-08-28 Medizinische Hochschule Hannover Chimeric antigen receptor
EP4669343A1 (en) 2023-02-24 2025-12-31 Medizinische Hochschule Hannover CHIMERIC ANTIGEN RECIPIENT
CN121586582A (zh) 2023-03-20 2026-02-27 汉诺威医学院 嵌合抗原受体
EP4434539A1 (en) 2023-03-20 2024-09-25 Medizinische Hochschule Hannover Chimeric antigen receptor
CN118109416B (zh) * 2023-03-30 2024-11-22 广州百吉生物制药有限公司 功能增强型工程化免疫细胞及其制备和应用
EP4509522A1 (en) 2023-08-16 2025-02-19 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft A tgfbeta switch receptor, a nucleic acid encoding it, cells and pharmaceutical compositions comprising the same
WO2026008994A1 (en) 2024-07-04 2026-01-08 Quell Therapeutics Limited Expression construct
GB202411558D0 (en) 2024-08-06 2024-09-18 Quell Therapeutics Ltd Culture method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9304200D0 (en) 1993-03-02 1993-04-21 Sandoz Ltd Improvements in or relating to organic compounds
JP2011515493A (ja) 2008-03-27 2011-05-19 バーンハム インスティトゥート フォー メディカル リサーチ 抗原受容体により誘導されるＮＦ−κＢの活性化の阻害剤
EP3467101A3 (en) * 2010-09-08 2019-06-19 Baylor College of Medicine Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells
CN107164330A (zh) * 2011-04-08 2017-09-15 贝勒医学院 使用嵌合细胞因子受体逆转肿瘤微环境的影响
EP3549611B1 (en) * 2011-07-29 2021-06-30 The Trustees of the University of Pennsylvania Switch costimulatory receptors
CA2909701C (en) * 2013-04-17 2022-12-06 Baylor College Of Medicine Immunosuppressive tgf-.beta. signal converter

Also Published As

Publication number Publication date
JP2016520302A (ja) 2016-07-14
WO2014172584A1 (en) 2014-10-23
CN105452287A (zh) 2016-03-30
US20200140520A1 (en) 2020-05-07
CA2909701C (en) 2022-12-06
HK1220704A1 (en) 2017-05-12
EP3470423B1 (en) 2021-10-06
CA2909701A1 (en) 2014-10-23
EP3470423A1 (en) 2019-04-17
EP2986636B1 (en) 2018-11-14
EP2986636A1 (en) 2016-02-24
US20160075755A1 (en) 2016-03-17
US10584158B2 (en) 2020-03-10

Similar Documents

Publication Publication Date Title
JP6578271B2 (ja) 免疫抑制ＴＧＦ−βシグナルコンバーター
JP6821561B2 (ja) バイパータイト型およびトリパータイト型のシグナル伝達免疫細胞
JP6678215B2 (ja) がんにおけるｃｄ１３８の標的化
US20180079824A1 (en) HER2/ErbB2 Chimeric Antigen Receptor
HK1245841A1 (en) Targeting cd138 in cancer
JP2016513458A (ja) 化学療法耐性免疫細胞
HK1220704B (en) Immunosuppressive tgf-beta signal converter
HK1219981B (en) Targeting cd138 in cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170406

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170406

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180309

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190320

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190809

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190826

R150 Certificate of patent or registration of utility model

Ref document number: 6578271

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250